Results 91 to 100 of about 682 (125)

A Real-World Retrospective Study on the Efficacy and Safety of Four Antiviral Drugs for Hospitalized COVID-19 Patients: Nirmatrelvir/Ritonavir, Simnotrelvir/Ritonavir, Molnupiravir and Azvudine. [PDF]

Infect Drug Resist
Yu X, Luo R, Xie G, Ji J, Wang J, Li X, Qian X, Wang X.   +7 more
europepmc   +1 more source

Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals. [PDF]

Influenza Other Respir Viruses
Gao Y, Dong Y, Bu Q, Gong Z, Wang W, Zhou Z, Gao Y, Liu L, Wu M, Zhang J, Liang L, Li H, Jiang M, Luo Z, Ma Y, Zhang X, Hu Z.   +16 more
europepmc   +1 more source

Editorial: Drug development for respiratory infectious diseases and related complications in other systems. [PDF]

Front Med (Lausanne)
Yu X, Wang Y, Oliva A, Xue M.
europepmc   +1 more source

Identification of lead inhibitors for 3CLpro of SARS-CoV-2 target using machine learning based virtual screening, ADMET analysis, molecular docking and molecular dynamics simulations. [PDF]

RSC Adv
Chhetri SP, Bhandari VS, Maharjan R, Lamichhane TR.   +3 more
europepmc   +1 more source

Nirmatrelvir/ritonavir reduced mortality in severe or critical COVID-19 patients: a multicenter retrospective cohort study. [PDF]

Front Med (Lausanne)
Zhao H, Meng W, Lv X, Si S, Wu S, Li J, Cai Z, Jin R, Yang L, Li C, Song L.   +10 more
europepmc   +1 more source

Effectiveness of the antiviral medications azvudine and nirmatrelvir-ritonavir in treating COVID-19 in patients with hematological malignancies. [PDF]

Clinics (Sao Paulo)
Zeng Z, Li F, Zhong M, Zhu L, Chen W, Wang X.   +5 more
europepmc   +1 more source

Development and validation of a nomogram to assess the occurrence of liver dysfunction in patients with COVID-19 pneumonia in the ICU. [PDF]

BMC Infect Dis
Wang Z, Zhao L, Xie K.
europepmc   +1 more source

Comparative Analysis of Viral Load Quantification Using Reverse Transcription Polymerase Chain Reaction and Digital Droplet Polymerase Chain Reaction. [PDF]

Int J Mol Sci
Gebe Abreu Cabral P, Bastos de Souza S, Ferraz Arruda R, Passos de Figueiredo Cabral S, Leone Evangelista Monteiro de Assis A, Porto Muniz Martins Y, Brazil Viana Junior A, Chang J, Lei P, Martins da Silva R.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Azvudine and mortality in patients with coronavirus disease 2019: A retrospective cohort study

International Immunopharmacology, 2023
Several studies have found that azvudine (FNC) can inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication both in vivo and in vitro. However, the effect of FNC on the risk of death in patients with coronavirus disease 2019 (COVID-19) is unclear.
Bin Liu, Mingjin Yang, Li Xu, Yishi Li, Jing Cai, Bo Xie, Kaican Zong, Shuliang Guo   +7 more
openaire   +2 more sources

Separation and quantification of Azvudine in plasma of patients with COVID-19 using LC-MS/MS

Journal of Pharmaceutical and Biomedical Analysis, 2023
Azvudine (FNC) is a new drug conditionally approved in 2022 for the treatment of coronavirus disease 2019 (COVID-19) in China. However, the exposure level of FNC in COVID-19 patients in clinical practice is still obscure, and there is no liquid chromatography-tandem mass spectrometry (LC-MS/MS) or LC method reported for quantifying the FNC.
Zhijun Liu, Fengying Liang, Shouhong Gao, Xiujing Zhu, Xinhua Song, Wansheng Chen, Xia Tao, Zhipeng Wang, Deduo Xu   +8 more
openaire   +2 more sources